With an average analyst rating of buy, Teva Pharmaceutical Industries is clearly an analyst favorite. But the analysts could be wrong. Is TEVA overvalued at today's price of $16.74? Let's take a closer look at the fundamentals to find out.
The first step in determining whether a stock is overvalued is to check its price to book (P/B) ratio. This is perhaps the most basic measure of a company's valuation, which is its market value divided by its book value. Book value refers to the sum of all of the company's assets minus its liabilities -- you can also think of it as the company's equity value.
Traditionally, value investors would look for companies with a ratio of less than 1 (meaning that the market value was smaller than the company's book value), but such opportunities are very rare these days. So we tend to look for company's whose valuations are less than their sector and market average. The P/B ratio for Teva Pharmaceutical Industries is 3.13, compared to its sector average of 3.53 and the S&P 500's average P/B of 4.74.
Modernly, the most common metric for valuing a company is its Price to Earnings (P/E) ratio. It's simply today's stock price of 16.74 divided by either its trailing or forward earnings, which for Teva Pharmaceutical Industries are $-0.85 and $2.77 respectively. Based on these values, the company's trailing P/E ratio is -19.7 and its forward P/E ratio is 6.0. By way of comparison, the average P/E ratio of the Health Care sector is 26.07 and the average P/E ratio of the S&P 500 is 29.3.
Indebted or mismanaged companies can't sustain shareholder value for long, even if they have strong earnings. For this reason, considering Teva Pharmaceutical Industries's ability to meet its debt obligations is also an important aspect of pinning down its valuation. By adding up its current assets, then subtracting its inventory and prepaid expenses, and then dividing the whole by its current liabilities, we obtain the company's Quick Ratio of 0.491. Since TEVA's is lower than 1, it does not have the liquidity necessary to meet its current liabilities.
When we had up all the inflows and outflows of cash, including payments to creditors, we obtain Teva Pharmaceutical Industries's levered free cash flow of $1.37 Billion. This represents the money left over from the company's operations that is available for reinvestment in the business, or for paying out to equity investors in the form of a dividend. Despite its positive cash flows, Teva Pharmaceutical Industries does not currently pay a dividend.
Shares of Teva Pharmaceutical Industries appear to be overvalued at today's prices — despite the positive outlook from analysts. But sometimes stocks with inflated valuations turn out to be strong performances for years, and even decades, such as Amazon. So be sure to do your own due diligence if you are interested in taking a long position in TEVA.
